Radiopharm Theranostics (ASX:RAD) has announced the appointment of Dr Sherin Al-Safadi as its vice president of medical and corporate affairs.
The company is developing a platform of radiopharmaceutical products for both diagnostic and therapeutic uses.
Most recently, Dr Al-Safadi held the vice-president of medical affairs at POINT Biopharma, where she assembled and headed up a medical affairs division and led the strategic and tactical planning for Phase 3 support and launch preparation of radiopharmaceuticals. She also provided strategic input and leadership for business development and licensing opportunities.
She is co-founder and president at Foundation Amal (Canada-US), overseeing an executive leadership team of 12 directors and members.
Previously, she held leadership roles at multinational pharmaceutical and biotechnology companies, including Bayer, where she served as the director of global medical affairs for oncology.
"We are thrilled to have Sherin join our team at Radiopharm Theranostics," said Riccardo Canevari, the managing director and CEO of Radiopharm. "Her expertise and leadership skills will be invaluable as we continue to grow and develop our pipeline of radiopharmaceutical products. In particular, with F18- Pivalate entering late-stage development, the Medical Affairs function becomes a critical success factor."